Brentuximab vedotin (anti-CD30) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin (anti-CD30) can be used for the research of relapsed and refractory Hodgkin lymphoma. Purity >90% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg
Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂
No
储存条件
-80℃储存,避免反复冻融
运输条件
特低温运输
稳定性与储存
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
图片
Brentuximab vedotin (anti-CD30) (Ab175479) - Flow Cytometry Flow Cytometry analysis of Jurkat cells labelling CD30 (red) with Brentuximab vedotin (anti-CD30) (Ab175479). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Brentuximab vedotin (anti-CD30) (Ab175479) - Flow Cytometry Flow Cytometry analysis of K562 cells labelling CD30 (red) with Brentuximab vedotin (anti-CD30) (Ab175479). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Brentuximab vedotin (anti-CD30) (Ab175479) - ELISA Immobilized Recombinant Human CD30 protein (rp169577) at 1.0 μg/mL can bind Brentuximab vedotin (anti-CD30) (Ab175479) with the EC50 of 84.31 ng/mL.
Brentuximab vedotin (anti-CD30) (Ab175479) - SEC The purity of Brentuximab vedotin (anti-CD30) (Ab175479) is more than 95% verified by HPLC.